Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Bristol-Myers Squibb Co. et al v. Merck & Co., Inc. et al
Case Number:
1:15-cv-00572
Court:
Nature of Suit:
Judge:
Firms
Companies
- Bristol-Myers Squibb Co.
- Dana-Farber Cancer Institute Inc.
- Merck & Co. Inc.
- Ono Pharmaceutical Co. Ltd
Sectors & Industries:
-
January 20, 2017
Merck Pays Bristol-Myers $625M In Cancer Treatment IP Row
Merck will pay Bristol-Myers Squibb $625 million to end an ongoing intellectual property battle over an immunotherapy cancer treatment, the companies announced on Friday, ending multiple cases including three lawsuits in Delaware federal court and setting up a 10-year licensing agreement.
-
March 31, 2016
BMS Cancer Treatment Patent Survives Merck Attack, For Now
A Delaware federal judge on Tuesday refused to dismiss a suit by Bristol-Myers Squibb accusing Merck of infringing a patent for its immunotherapy cancer treatment, saying that although the patent is directed to a natural phenomenon, further discovery is needed to determine if it is invalid.
-
July 07, 2015
BMS Sues Merck As Soon As USPTO Grants Cancer Patent
Bristol-Myers Squibb Co. went after Merck and Co. in Delaware federal court Tuesday for allegedly infringing on its immunotherapy cancer treatment, filing the suit on the same day that the U.S. Patent and Trademark Office granted Bristol-Myers a patent for the process.